VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q89863701 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241120235938.0
008 241120nneanz||abbn n and d
035 ‎‡a (WKP)Q89863701‏
024 ‎‡a 0000-0002-1926-0043‏ ‎‡2 orcid‏
035 ‎‡a (OCoLC)Q89863701‏
100 0 ‎‡a Anna Bal-Price‏ ‎‡c researcher‏ ‎‡9 en‏
375 ‎‡a 2‏ ‎‡2 iso5218‏
400 0 ‎‡a Anna Bal-Price‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
670 ‎‡a Author's A human pluripotent carcinoma stem cell-based model for in vitro developmental neurotoxicity testing: effects of methylmercury, lead and aluminum evaluated by gene expression studies‏
670 ‎‡a Author's A multi-laboratory evaluation of microelectrode array-based measurements of neural network activity for acute neurotoxicity testing.‏
670 ‎‡a Author's Advanced Good Cell Culture Practice for human primary, stem cell-derived and organoid models as well as microphysiological systems‏
670 ‎‡a Author's Advancing human health risk assessment‏
670 ‎‡a Author's Adverse outcome pathways: Application to enhance mechanistic understanding of neurotoxicity‏
670 ‎‡a Author's Alternative‏
670 ‎‡a Author's Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010.‏
670 ‎‡a Author's An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition.‏
670 ‎‡a Author's An analysis of the limitations and uncertainties of in vivo developmental neurotoxicity testing and assessment to identify the potential for alternative approaches‏
670 ‎‡a Author's Assessment of developmental neurotoxicity induced by chemical mixtures using an adverse outcome pathway concept‏
670 ‎‡a Author's Brain-on-a-chip model enables analysis of human neuronal differentiation and chemotaxis‏
670 ‎‡a Author's Consensus statement on the need for innovation, transition and implementation of developmental neurotoxicity (DNT) testing for regulatory purposes‏
670 ‎‡a Author's Corrigendum to Recommendation on test readiness criteria for new approach methods in toxicology: exemplified for developmental neurotoxicity‏
670 ‎‡a Author's Developing and applying the adverse outcome pathway concept for understanding and predicting neurotoxicity‏
670 ‎‡a Author's Development and analysis of an adverse outcome pathway network for human neurotoxicity‏
670 ‎‡a Author's Development of a mechanistically-based genetically engineered PC12 cell system to detect p53-mediated cytotoxicity‏
670 ‎‡a Author's Development of the Adverse Outcome Pathway‏
670 ‎‡a Author's Development of the Adverse Outcome Pathway (AOP): Chronic binding of antagonist to N-methyl-d-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities of children‏
670 ‎‡a Author's Developmental neurotoxicity testing: recommendations for developing alternative methods for the screening and prioritization of chemicals.‏
670 ‎‡a Author's Early life exposure to air pollution particulate matter‏
670 ‎‡a Author's Early life exposure to air pollution particulate matter (PM) as risk factor for attention deficit/hyperactivity disorder (ADHD): Need for novel strategies for mechanisms and causalities.‏
670 ‎‡a Author's Editorial: Developmental neurotoxicity‏
670 ‎‡a Author's Evaluation of drug-induced neurotoxicity based on metabolomics, proteomics and electrical activity measurements in complementary CNS in vitro models‏
670 ‎‡a Author's Evaluation of the rotenone-induced activation of the Nrf2 pathway in a neuronal model derived from human induced pluripotent stem cells‏
670 ‎‡a Author's Gene expression as a sensitive endpoint to evaluate cell differentiation and maturation of the developing central nervous system in primary cultures of rat cerebellar granule cells‏
670 ‎‡a Author's Gene expression as a sensitive endpoint to evaluate cell differentiation and maturation of the developing central nervous system in primary cultures of rat cerebellar granule cells (CGCs) exposed to pesticides‏
670 ‎‡a Author's Genomic and phenotypic alterations of the neuronal-like cells derived from human embryonal carcinoma stem cells‏
670 ‎‡a Author's Genomic and phenotypic alterations of the neuronal-like cells derived from human embryonal carcinoma stem cells (NT2) caused by exposure to organophosphorus compounds paraoxon and mipafox‏
670 ‎‡a Author's Good Cell and Tissue Culture Practice 2.0 (GCCP 2.0) - Draft for stakeholder discussion and call for action‏
670 ‎‡a Author's Good Cell Culture Practice for stem cells and stem-cell-derived models.‏
670 ‎‡a Author's Guidance on good cell culture practice. a report of the second ECVAM task force on good cell culture practice‏
670 ‎‡a Author's Highly purified lipoteichoic acid induced pro-inflammatory signalling in primary culture of rat microglia through Toll-like receptor 2: selective potentiation of nitric oxide production by muramyl dipeptide‏
670 ‎‡a Author's Inflammatory neurodegeneration induced by lipoteichoic acid from Staphylococcus aureus is mediated by glia activation, nitrosative and oxidative stress, and caspase activation‏
670 ‎‡a Author's Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria‏
670 ‎‡a Author's Inhibition of microglial phagocytosis is sufficient to prevent inflammatory neuronal death‏
670 ‎‡a Author's Integrating biokinetics and in vitro studies to evaluate developmental neurotoxicity induced by chlorpyrifos in human iPSC-derived neural stem cells undergoing differentiation towards neuronal and glial cells‏
670 ‎‡a Author's International Regulatory and Scientific Effort for Improved Developmental Neurotoxicity Testing‏
670 ‎‡a Author's International STakeholder NETwork‏
670 ‎‡a Author's International STakeholder NETwork (ISTNET): creating a developmental neurotoxicity (DNT) testing road map for regulatory purposes‏
670 ‎‡a Author's International STakeholder NETwork (ISTNET) for creating a developmental neurotoxicity testing (DNT) roadmap for regulatory purposes‏
670 ‎‡a Author's Investigating cell type specific mechanisms contributing to acute oral toxicity‏
670 ‎‡a Author's Investigation into experimental toxicological properties of plant protection products having a potential link to Parkinson's disease and childhood leukaemia†‏
670 ‎‡a Author's Mechanisms of toxicity induced by SiO2 nanoparticles of in vitro human alveolar barrier: effects on cytokine production, oxidative stress induction, surfactant proteins A mRNA expression and nanoparticles uptake.‏
670 ‎‡a Author's Message from the Editor-in-Chief‏
670 ‎‡a Author's miRNA expression profiling in a human stem cell-based model as a tool for developmental neurotoxicity testing‏
670 ‎‡a Author's mRNA expression is a relevant tool to identify developmental neurotoxicants using an in vitro approach‏
670 ‎‡a Author's Nitric oxide induces rapid, calcium-dependent release of vesicular glutamate and ATP from cultured rat astrocytes‏
670 ‎‡a Author's Nitric oxide stimulates PC12 cell proliferation via cGMP and inhibits at higher concentrations mainly via energy depletion‏
670 ‎‡a Author's Nrf2 pathway activation upon rotenone treatment in human iPSC-derived neural stem cells undergoing differentiation towards neurons and astrocytes‏
670 ‎‡a Author's OECD/EFSA workshop on developmental neurotoxicity‏
670 ‎‡a Author's OECD/EFSA workshop on developmental neurotoxicity (DNT): The use of non-animal test methods for regulatory purposes.‏
670 ‎‡a Author's Overcoming barriers to validation of non-animal partial replacement methods/Integrated Testing Strategies: the report of an EPAA-ECVAM workshop.‏
670 ‎‡a Author's Protocol for the Differentiation of Human Induced Pluripotent Stem Cells into Mixed Cultures of Neurons and Glia for Neurotoxicity Testing‏
670 ‎‡a Author's Putative adverse outcome pathways relevant to neurotoxicity‏
670 ‎‡a Author's Recommendation on test readiness criteria for new approach methods in toxicology: Exemplified for developmental neurotoxicity‏
670 ‎‡a Author's Reference compounds for alternative test methods to indicate developmental neurotoxicity (DNT) potential of chemicals: example lists and criteria for their selection and use.‏
670 ‎‡a Author's Representing the Process of Inflammation as Key Events in Adverse Outcome Pathways‏
670 ‎‡a Author's Stimulation of the NADPH oxidase in activated rat microglia removes nitric oxide but induces peroxynitrite production‏
670 ‎‡a Author's Strategies to improve the regulatory assessment of developmental neurotoxicity‏
670 ‎‡a Author's Strategies to improve the regulatory assessment of developmental neurotoxicity (DNT) using in vitro methods‏
670 ‎‡a Author's The value of alternative testing for neurotoxicity in the context of regulatory needs‏
670 ‎‡a Author's Workgroup report: incorporating in vitro alternative methods for developmental neurotoxicity into international hazard and risk assessment strategies‏
909 ‎‡a (orcid) 0000000219260043‏ ‎‡9 1‏
912 ‎‡a alternative‏ ‎‡A Alternative‏ ‎‡9 1‏
919 ‎‡a putativeadverseoutcomepathwaysrelevanttoneurotoxicity‏ ‎‡A Putative adverse outcome pathways relevant to neurotoxicity‏ ‎‡9 1‏
919 ‎‡a workgroupreportincorporatinginvitroalternativemethodsfordevelopmentalneurotoxicityintointernationalhazardandriskassessmentstrategies‏ ‎‡A Workgroup report: incorporating in vitro alternative methods for developmental neurotoxicity into international hazard and risk assessment strategies‏ ‎‡9 1‏
919 ‎‡a valueofalternativetestingforneurotoxicityinthecontextofregulatoryneeds‏ ‎‡A The value of alternative testing for neurotoxicity in the context of regulatory needs‏ ‎‡9 1‏
919 ‎‡a strategiestoimprovetheregulatoryassessmentofdevelopmentalneurotoxicitydntusinginvitromethods‏ ‎‡A Strategies to improve the regulatory assessment of developmental neurotoxicity (DNT) using in vitro methods‏ ‎‡9 1‏
919 ‎‡a strategiestoimprovetheregulatoryassessmentofdevelopmentalneurotoxicity‏ ‎‡A Strategies to improve the regulatory assessment of developmental neurotoxicity‏ ‎‡9 1‏
919 ‎‡a stimulationofthenadphoxidaseinactivatedratmicrogliaremovesnitricoxidebutinducesperoxynitriteproduction‏ ‎‡A Stimulation of the NADPH oxidase in activated rat microglia removes nitric oxide but induces peroxynitrite production‏ ‎‡9 1‏
919 ‎‡a representingtheprocessofinflammationaskeyeventsinadverseoutcomepathways‏ ‎‡A Representing the Process of Inflammation as Key Events in Adverse Outcome Pathways‏ ‎‡9 1‏
919 ‎‡a referencecompoundsforalternativetestmethodstoindicatedevelopmentalneurotoxicitydntpotentialofchemicalsexamplelistsandcriteriafortheirselectionanduse‏ ‎‡A Reference compounds for alternative test methods to indicate developmental neurotoxicity (DNT) potential of chemicals: example lists and criteria for their selection and use.‏ ‎‡9 1‏
919 ‎‡a recommendationontestreadinesscriteriafornewapproachmethodsintoxicologyexemplifiedfordevelopmentalneurotoxicity‏ ‎‡A Recommendation on test readiness criteria for new approach methods in toxicology: Exemplified for developmental neurotoxicity‏ ‎‡9 1‏
919 ‎‡a humanpluripotentcarcinomastemcellbasedmodelforinvitrodevelopmentalneurotoxicitytestingeffectsofmethylmercuryleadandaluminumevaluatedbygeneexpressionstudies‏ ‎‡A A human pluripotent carcinoma stem cell-based model for in vitro developmental neurotoxicity testing: effects of methylmercury, lead and aluminum evaluated by gene expression studies‏ ‎‡9 1‏
919 ‎‡a multilaboratoryevaluationofmicroelectrodearraybasedmeasurementsofneuralnetworkactivityforacuteneurotoxicitytesting‏ ‎‡A A multi-laboratory evaluation of microelectrode array-based measurements of neural network activity for acute neurotoxicity testing.‏ ‎‡9 1‏
919 ‎‡a advancedgoodcellculturepracticeforhumanprimarystemcellderivedandorganoidmodelsaswellasmicrophysiologicalsystems‏ ‎‡A Advanced Good Cell Culture Practice for human primary, stem cell-derived and organoid models as well as microphysiological systems‏ ‎‡9 1‏
919 ‎‡a advancinghumanhealthriskassessment‏ ‎‡A Advancing human health risk assessment‏ ‎‡9 1‏
919 ‎‡a adverseoutcomepathwaysapplicationtoenhancemechanisticunderstandingofneurotoxicity‏ ‎‡A Adverse outcome pathways: Application to enhance mechanistic understanding of neurotoxicity‏ ‎‡9 1‏
919 ‎‡a alternativenonanimalmethodsforcosmeticstestingcurrentstatusandfutureprospects‏ ‎‡A Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010.‏ ‎‡9 1‏
919 ‎‡a adverseoutcomepathwayforparkinsonianmotordeficitsassociatedwithmitochondrialcomplex1inhibition‏ ‎‡A An adverse outcome pathway for parkinsonian motor deficits associated with mitochondrial complex I inhibition.‏ ‎‡9 1‏
919 ‎‡a analysisofthelimitationsanduncertaintiesofinvivodevelopmentalneurotoxicitytestingandassessmenttoidentifythepotentialforalternativeapproaches‏ ‎‡A An analysis of the limitations and uncertainties of in vivo developmental neurotoxicity testing and assessment to identify the potential for alternative approaches‏ ‎‡9 1‏
919 ‎‡a assessmentofdevelopmentalneurotoxicityinducedbychemicalmixturesusinganadverseoutcomepathwayconcept‏ ‎‡A Assessment of developmental neurotoxicity induced by chemical mixtures using an adverse outcome pathway concept‏ ‎‡9 1‏
919 ‎‡a brainonachipmodelenablesanalysisofhumanneuronaldifferentiationandchemotaxis‏ ‎‡A Brain-on-a-chip model enables analysis of human neuronal differentiation and chemotaxis‏ ‎‡9 1‏
919 ‎‡a consensusstatementontheneedforinnovationtransitionandimplementationofdevelopmentalneurotoxicitydnttestingforregulatorypurposes‏ ‎‡A Consensus statement on the need for innovation, transition and implementation of developmental neurotoxicity (DNT) testing for regulatory purposes‏ ‎‡9 1‏
919 ‎‡a corrigendumtorecommendationontestreadinesscriteriafornewapproachmethodsintoxicologyexemplifiedfordevelopmentalneurotoxicity‏ ‎‡A Corrigendum to Recommendation on test readiness criteria for new approach methods in toxicology: exemplified for developmental neurotoxicity‏ ‎‡9 1‏
919 ‎‡a developingandapplyingtheadverseoutcomepathwayconceptforunderstandingandpredictingneurotoxicity‏ ‎‡A Developing and applying the adverse outcome pathway concept for understanding and predicting neurotoxicity‏ ‎‡9 1‏
919 ‎‡a developmentandanalysisofanadverseoutcomepathwaynetworkforhumanneurotoxicity‏ ‎‡A Development and analysis of an adverse outcome pathway network for human neurotoxicity‏ ‎‡9 1‏
919 ‎‡a developmentofamechanisticallybasedgeneticallyengineeredpc12cellsystemtodetectp53mediatedcytotoxicity‏ ‎‡A Development of a mechanistically-based genetically engineered PC12 cell system to detect p53-mediated cytotoxicity‏ ‎‡9 1‏
919 ‎‡a developmentoftheadverseoutcomepathway‏ ‎‡A Development of the Adverse Outcome Pathway‏ ‎‡9 1‏
919 ‎‡a developmentoftheadverseoutcomepathwayaopchronicbindingofantagonisttonmethyl500aspartatereceptorsnmdarsduringbraindevelopmentinducesimpairmentoflearningandmemoryabilitiesofchildren‏ ‎‡A Development of the Adverse Outcome Pathway (AOP): Chronic binding of antagonist to N-methyl-d-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities of children‏ ‎‡9 1‏
919 ‎‡a developmentalneurotoxicitytestingrecommendationsfordevelopingalternativemethodsforthescreeningandprioritizationofchemicals‏ ‎‡A Developmental neurotoxicity testing: recommendations for developing alternative methods for the screening and prioritization of chemicals.‏ ‎‡9 1‏
919 ‎‡a earlylifeexposuretoairpollutionparticulatematter‏ ‎‡A Early life exposure to air pollution particulate matter‏ ‎‡9 1‏
919 ‎‡a earlylifeexposuretoairpollutionparticulatematterpmasriskfactorforattentiondeficithyperactivitydisorderadhdneedfornovelstrategiesformechanismsandcausalities‏ ‎‡A Early life exposure to air pollution particulate matter (PM) as risk factor for attention deficit/hyperactivity disorder (ADHD): Need for novel strategies for mechanisms and causalities.‏ ‎‡9 1‏
919 ‎‡a editorialdevelopmentalneurotoxicity‏ ‎‡A Editorial: Developmental neurotoxicity‏ ‎‡9 1‏
919 ‎‡a evaluationofdruginducedneurotoxicitybasedonmetabolomicsproteomicsandelectricalactivitymeasurementsincomplementarycnsinvitromodels‏ ‎‡A Evaluation of drug-induced neurotoxicity based on metabolomics, proteomics and electrical activity measurements in complementary CNS in vitro models‏ ‎‡9 1‏
919 ‎‡a evaluationoftherotenoneinducedactivationofthenrf2pathwayinaneuronalmodelderivedfromhumaninducedpluripotentstemcells‏ ‎‡A Evaluation of the rotenone-induced activation of the Nrf2 pathway in a neuronal model derived from human induced pluripotent stem cells‏ ‎‡9 1‏
919 ‎‡a geneexpressionasasensitiveendpointtoevaluatecelldifferentiationandmaturationofthedevelopingcentralnervoussysteminprimaryculturesofratcerebellargranulecells‏ ‎‡A Gene expression as a sensitive endpoint to evaluate cell differentiation and maturation of the developing central nervous system in primary cultures of rat cerebellar granule cells‏ ‎‡9 1‏
919 ‎‡a geneexpressionasasensitiveendpointtoevaluatecelldifferentiationandmaturationofthedevelopingcentralnervoussysteminprimaryculturesofratcerebellargranulecellscgcsexposedtopesticides‏ ‎‡A Gene expression as a sensitive endpoint to evaluate cell differentiation and maturation of the developing central nervous system in primary cultures of rat cerebellar granule cells (CGCs) exposed to pesticides‏ ‎‡9 1‏
919 ‎‡a genomicandphenotypicalterationsoftheneuronallikecellsderivedfromhumanembryonalcarcinomastemcells‏ ‎‡A Genomic and phenotypic alterations of the neuronal-like cells derived from human embryonal carcinoma stem cells‏ ‎‡9 1‏
919 ‎‡a genomicandphenotypicalterationsoftheneuronallikecellsderivedfromhumanembryonalcarcinomastemcellsnt2causedbyexposuretoorganophosphoruscompoundsparaoxonandmipafox‏ ‎‡A Genomic and phenotypic alterations of the neuronal-like cells derived from human embryonal carcinoma stem cells (NT2) caused by exposure to organophosphorus compounds paraoxon and mipafox‏ ‎‡9 1‏
919 ‎‡a goodcellandtissueculturepractice20gccp20draftforstakeholderdiscussionandcallforaction‏ ‎‡A Good Cell and Tissue Culture Practice 2.0 (GCCP 2.0) - Draft for stakeholder discussion and call for action‏ ‎‡9 1‏
919 ‎‡a goodcellculturepracticeforstemcellsandstemcellderivedmodels‏ ‎‡A Good Cell Culture Practice for stem cells and stem-cell-derived models.‏ ‎‡9 1‏
919 ‎‡a guidanceongoodcellculturepracticeareportofthe2ecvamtaskforceongoodcellculturepractice‏ ‎‡A Guidance on good cell culture practice. a report of the second ECVAM task force on good cell culture practice‏ ‎‡9 1‏
919 ‎‡a highlypurifiedlipoteichoicacidinducedproinflammatorysignallinginprimarycultureofratmicrogliathroughtolllikereceptor2selectivepotentiationofnitricoxideproductionbymuramyldipeptide‏ ‎‡A Highly purified lipoteichoic acid induced pro-inflammatory signalling in primary culture of rat microglia through Toll-like receptor 2: selective potentiation of nitric oxide production by muramyl dipeptide‏ ‎‡9 1‏
919 ‎‡a inflammatoryneurodegenerationinducedbylipoteichoicacidfromstaphylococcusaureusismediatedbygliaactivationnitrosativeandoxidativestressandcaspaseactivation‏ ‎‡A Inflammatory neurodegeneration induced by lipoteichoic acid from Staphylococcus aureus is mediated by glia activation, nitrosative and oxidative stress, and caspase activation‏ ‎‡9 1‏
919 ‎‡a inflammatoryneurodegenerationmediatedbynitricoxideglutamateandmitochondria‏ ‎‡A Inflammatory neurodegeneration mediated by nitric oxide, glutamate, and mitochondria‏ ‎‡9 1‏
919 ‎‡a inhibitionofmicrogli Alpha gocytosisissufficienttopreventinflammatoryneuronaldeath‏ ‎‡A Inhibition of microglial phagocytosis is sufficient to prevent inflammatory neuronal death‏ ‎‡9 1‏
919 ‎‡a integratingbiokineticsandinvitrostudiestoevaluatedevelopmentalneurotoxicityinducedbychlorpyrifosinhumanipscderivedneuralstemcellsundergoingdifferentiationtowardsneuronalandglialcells‏ ‎‡A Integrating biokinetics and in vitro studies to evaluate developmental neurotoxicity induced by chlorpyrifos in human iPSC-derived neural stem cells undergoing differentiation towards neuronal and glial cells‏ ‎‡9 1‏
919 ‎‡a internationalregulatoryandscientificeffortforimproveddevelopmentalneurotoxicitytesting‏ ‎‡A International Regulatory and Scientific Effort for Improved Developmental Neurotoxicity Testing‏ ‎‡9 1‏
919 ‎‡a internationalstakeholdernetwork‏ ‎‡A International STakeholder NETwork‏ ‎‡9 1‏
919 ‎‡a internationalstakeholdernetworkistnetcreatingadevelopmentalneurotoxicitydnttestingroadmapforregulatorypurposes‏ ‎‡A International STakeholder NETwork (ISTNET): creating a developmental neurotoxicity (DNT) testing road map for regulatory purposes‏ ‎‡9 1‏
919 ‎‡a internationalstakeholdernetworkistnetforcreatingadevelopmentalneurotoxicitytestingdntroadmapforregulatorypurposes‏ ‎‡A International STakeholder NETwork (ISTNET) for creating a developmental neurotoxicity testing (DNT) roadmap for regulatory purposes‏ ‎‡9 1‏
919 ‎‡a investigatingcelltypespecificmechanismscontributingtoacuteoraltoxicity‏ ‎‡A Investigating cell type specific mechanisms contributing to acute oral toxicity‏ ‎‡9 1‏
919 ‎‡a investigationintoexperimentaltoxicologicalpropertiesofplantprotectionproductshavingapotentiallinktoparkinsonsdiseaseandchildhoodleukaemia‏ ‎‡A Investigation into experimental toxicological properties of plant protection products having a potential link to Parkinson's disease and childhood leukaemia†‏ ‎‡9 1‏
919 ‎‡a mechanismsoftoxicityinducedbysio2nanoparticlesofinvitrohumanalveolarbarriereffectsoncytokineproductionoxidativestressinductionsurfactantproteinsamrnaexpressionandnanoparticlesuptake‏ ‎‡A Mechanisms of toxicity induced by SiO2 nanoparticles of in vitro human alveolar barrier: effects on cytokine production, oxidative stress induction, surfactant proteins A mRNA expression and nanoparticles uptake.‏ ‎‡9 1‏
919 ‎‡a messagefromtheeditorinchief‏ ‎‡A Message from the Editor-in-Chief‏ ‎‡9 1‏
919 ‎‡a mirnaexpressionprofilinginahumanstemcellbasedmodelasatoolfordevelopmentalneurotoxicitytesting‏ ‎‡A miRNA expression profiling in a human stem cell-based model as a tool for developmental neurotoxicity testing‏ ‎‡9 1‏
919 ‎‡a mrnaexpressionisarelevanttooltoidentifydevelopmentalneurotoxicantsusinganinvitroapproach‏ ‎‡A mRNA expression is a relevant tool to identify developmental neurotoxicants using an in vitro approach‏ ‎‡9 1‏
919 ‎‡a nitricoxideinducesrapidcalciumdependentreleaseofvesicularglutamateandatpfromculturedratastrocytes‏ ‎‡A Nitric oxide induces rapid, calcium-dependent release of vesicular glutamate and ATP from cultured rat astrocytes‏ ‎‡9 1‏
919 ‎‡a nitricoxidestimulatespc12cellproliferationviacgmpandinhibitsathigherconcentrationsmainlyviaenergydepletion‏ ‎‡A Nitric oxide stimulates PC12 cell proliferation via cGMP and inhibits at higher concentrations mainly via energy depletion‏ ‎‡9 1‏
919 ‎‡a nrf2pathwayactivationuponrotenonetreatmentinhumanipscderivedneuralstemcellsundergoingdifferentiationtowardsneuronsandastrocytes‏ ‎‡A Nrf2 pathway activation upon rotenone treatment in human iPSC-derived neural stem cells undergoing differentiation towards neurons and astrocytes‏ ‎‡9 1‏
919 ‎‡a oecdefsaworkshopondevelopmentalneurotoxicity‏ ‎‡A OECD/EFSA workshop on developmental neurotoxicity‏ ‎‡9 1‏
919 ‎‡a oecdefsaworkshopondevelopmentalneurotoxicitydnttheuseofnonanimaltestmethodsforregulatorypurposes‏ ‎‡A OECD/EFSA workshop on developmental neurotoxicity (DNT): The use of non-animal test methods for regulatory purposes.‏ ‎‡9 1‏
919 ‎‡a overcomingbarrierstovalidationofnonanimalpartialreplacementmethodsintegratedtestingstrategiesthereportofanepaaecvamworkshop‏ ‎‡A Overcoming barriers to validation of non-animal partial replacement methods/Integrated Testing Strategies: the report of an EPAA-ECVAM workshop.‏ ‎‡9 1‏
919 ‎‡a protocolforthedifferentiationofhumaninducedpluripotentstemcellsintomixedculturesofneuronsandgliaforneurotoxicitytesting‏ ‎‡A Protocol for the Differentiation of Human Induced Pluripotent Stem Cells into Mixed Cultures of Neurons and Glia for Neurotoxicity Testing‏ ‎‡9 1‏
943 ‎‡a 201x‏ ‎‡A 2010‏ ‎‡9 1‏
946 ‎‡a a‏ ‎‡9 1‏
996 ‎‡2 ISNI|0000000024238604‏
996 ‎‡2 J9U|987007388575205171‏
996 ‎‡2 LC|n 2001022114‏
996 ‎‡2 BIBSYS|2131256‏
996 ‎‡2 ISNI|0000000455675929‏
996 ‎‡2 J9U|987007414717405171‏
996 ‎‡2 LC|n 86806983‏
996 ‎‡2 J9U|987007405520205171‏
996 ‎‡2 ISNI|0000000023632562‏
996 ‎‡2 LC|n 84231363‏
996 ‎‡2 NII|DA08123106‏
996 ‎‡2 LC|n 2021181743‏
996 ‎‡2 DNB|1329538242‏
996 ‎‡2 LC|n 86108650‏
996 ‎‡2 SUDOC|270390219‏
996 ‎‡2 SUDOC|203354613‏
996 ‎‡2 LC|nb2007025362‏
996 ‎‡2 LC|n 2020018371‏
996 ‎‡2 BNE|XX1052510‏
996 ‎‡2 ISNI|0000000496410433‏
996 ‎‡2 NUKAT|n 2011063995‏
996 ‎‡2 LIH|LNB:DJ_e__y_;=B8‏
996 ‎‡2 LC|nb2009005053‏
996 ‎‡2 LC|n 87135583‏
996 ‎‡2 SUDOC|033494673‏
996 ‎‡2 SZ|123157552‏
996 ‎‡2 LC|n 90698930‏
996 ‎‡2 BNF|12278899‏
996 ‎‡2 ISNI|0000000053479095‏
996 ‎‡2 N6I|vtls002016362‏
996 ‎‡2 LC|n 91072650‏
996 ‎‡2 SUDOC|169822532‏
996 ‎‡2 LC|nb2007012488‏
996 ‎‡2 BIBSYS|90524487‏
996 ‎‡2 LC|n 93099946‏
996 ‎‡2 SUDOC|230184561‏
996 ‎‡2 CAOONL|ncf10239188‏
996 ‎‡2 J9U|987007330805205171‏
996 ‎‡2 J9U|987007432096905171‏
996 ‎‡2 LC|no2019036117‏
996 ‎‡2 NII|DA01188599‏
996 ‎‡2 J9U|987007343239605171‏
996 ‎‡2 ISNI|0000000074451024‏
996 ‎‡2 ISNI|0000000073805441‏
996 ‎‡2 ISNI|0000000028677508‏
996 ‎‡2 N6I|vtls002452627‏
996 ‎‡2 CAOONL|ncf10058782‏
996 ‎‡2 LC|n 89120460‏
996 ‎‡2 SUDOC|225582589‏
996 ‎‡2 RERO|A003711589‏
996 ‎‡2 LC|nr 97008141‏
996 ‎‡2 LC|no2010033525‏
996 ‎‡2 LC|no2015034653‏
996 ‎‡2 CAOONL|ncf10514178‏
996 ‎‡2 LC|nr 93031612‏
996 ‎‡2 J9U|987007457221505171‏
996 ‎‡2 ISNI|000000002767660X‏
996 ‎‡2 ISNI|0000000034394424‏
996 ‎‡2 BIBSYS|90055338‏
996 ‎‡2 NUKAT|n 2010075635‏
996 ‎‡2 ISNI|0000000500193153‏
996 ‎‡2 LC|no2004026507‏
996 ‎‡2 LC|n 83234856‏
996 ‎‡2 ISNI|0000000460194388‏
996 ‎‡2 ISNI|0000000040758001‏
996 ‎‡2 SUDOC|161992234‏
996 ‎‡2 NTA|068495595‏
996 ‎‡2 LC|no2015009146‏
996 ‎‡2 J9U|987007462287505171‏
996 ‎‡2 ISNI|0000000029020540‏
996 ‎‡2 LC|n 83223455‏
996 ‎‡2 ISNI|0000000077544146‏
996 ‎‡2 ISNI|0000000054983197‏
996 ‎‡2 LC|n 85031463‏
996 ‎‡2 LC|n 2019244535‏
996 ‎‡2 BLBNB|000591511‏
996 ‎‡2 RERO|A003711667‏
996 ‎‡2 RERO|A003711666‏
996 ‎‡2 RERO|A003711664‏
996 ‎‡2 BNF|17120411‏
996 ‎‡2 J9U|987007266766505171‏
996 ‎‡2 NTA|322490103‏
996 ‎‡2 ISNI|0000000035553730‏
996 ‎‡2 NUKAT|n 01015150‏
996 ‎‡2 LC|n 2004103360‏
996 ‎‡2 NKC|mzk2018989032‏
996 ‎‡2 LC|n 86135907‏
996 ‎‡2 J9U|987007418902305171‏
996 ‎‡2 LC|n 50020528‏
996 ‎‡2 ISNI|0000000048069761‏
996 ‎‡2 BIBSYS|90180591‏
996 ‎‡2 ISNI|0000000030675069‏
996 ‎‡2 SUDOC|267838441‏
996 ‎‡2 LC|n 84080789‏
996 ‎‡2 ISNI|0000000028105737‏
996 ‎‡2 LC|n 93070870‏
996 ‎‡2 LC|n 85031949‏
996 ‎‡2 BLBNB|000239505‏
996 ‎‡2 BIBSYS|6039643‏
996 ‎‡2 CAOONL|ncf10109026‏
996 ‎‡2 LC|n 77005813‏
996 ‎‡2 J9U|987010649954605171‏
996 ‎‡2 LC|n 85112174‏
996 ‎‡2 BNF|16561275‏
996 ‎‡2 RERO|A011687708‏
996 ‎‡2 LC|nr2006012116‏
996 ‎‡2 DNB|123157552‏
996 ‎‡2 NUKAT|n 2021084351‏
996 ‎‡2 NTA|238490602‏
996 ‎‡2 LC|no 91011838‏
996 ‎‡2 BIBSYS|13022415‏
996 ‎‡2 LC|no2019036534‏
996 ‎‡2 LC|nb2011009113‏
996 ‎‡2 LC|nr 96023630‏
996 ‎‡2 ISNI|000000007653160X‏
996 ‎‡2 LC|nr2006008602‏
996 ‎‡2 ISNI|0000000031560933‏
996 ‎‡2 LC|nb2008018814‏
996 ‎‡2 ISNI|0000000118794572‏
996 ‎‡2 NTA|151539294‏
996 ‎‡2 LC|n 79047890‏
996 ‎‡2 LC|no2014044158‏
996 ‎‡2 ISNI|0000000433153070‏
996 ‎‡2 ISNI|000000006332568X‏
996 ‎‡2 ISNI|0000000117371068‏
996 ‎‡2 LC|nb2011011874‏
996 ‎‡2 LC|no2020041985‏
996 ‎‡2 ISNI|0000000110781793‏
996 ‎‡2 NSK|000423288‏
996 ‎‡2 PLWABN|9813311335105606‏
996 ‎‡2 ISNI|0000000050095889‏
996 ‎‡2 LC|n 81065858‏
996 ‎‡2 LC|n 99047173‏
996 ‎‡2 SUDOC|098741004‏
996 ‎‡2 ISNI|0000000074219065‏
996 ‎‡2 PLWABN|9810548137005606‏
996 ‎‡2 NTA|074433679‏
996 ‎‡2 ISNI|0000000026394037‏
996 ‎‡2 LC|no 98033611‏
996 ‎‡2 LC|n 2019026585‏
996 ‎‡2 LC|n 2018186490‏
996 ‎‡2 LC|n 83187976‏
996 ‎‡2 DNB|1157902073‏
996 ‎‡2 BIBSYS|6085743‏
996 ‎‡2 J9U|987007362123105171‏
996 ‎‡2 LC|nr2001049074‏
996 ‎‡2 ISNI|0000000027464025‏
996 ‎‡2 ISNI|0000000510842508‏
996 ‎‡2 ISNI|0000000029837024‏
996 ‎‡2 ISNI|0000000054753594‏
996 ‎‡2 BNF|12437040‏
996 ‎‡2 ISNI|0000000028520957‏
996 ‎‡2 BIBSYS|90771880‏
996 ‎‡2 J9U|987007391806505171‏
996 ‎‡2 ISNI|0000000490287729‏
996 ‎‡2 NII|DA03066253‏
996 ‎‡2 LC|no2022072142‏
996 ‎‡2 LC|n 2018186006‏
996 ‎‡2 SUDOC|151820562‏
996 ‎‡2 ISNI|0000000079293926‏
996 ‎‡2 NUKAT|n 2016171869‏
996 ‎‡2 SUDOC|031606660‏
996 ‎‡2 NTA|090592522‏
996 ‎‡2 NUKAT|n 2016136145‏
996 ‎‡2 CAOONL|ncf11194646‏
996 ‎‡2 J9U|987012747981005171‏
996 ‎‡2 CAOONL|ncf11259654‏
996 ‎‡2 J9U|987007280762605171‏
996 ‎‡2 NUKAT|n 2006093144‏
996 ‎‡2 ISNI|0000000035080195‏
996 ‎‡2 ISNI|0000000369539461‏
996 ‎‡2 BIBSYS|98018691‏
996 ‎‡2 DNB|1292609575‏
996 ‎‡2 PLWABN|9813274201505606‏
996 ‎‡2 LC|n 91030195‏
996 ‎‡2 SIMACOB|320607331‏
996 ‎‡2 ISNI|0000000119704241‏
996 ‎‡2 CAOONL|ncf10458908‏
996 ‎‡2 LC|n 2005013631‏
996 ‎‡2 W2Z|1634281493355‏
996 ‎‡2 LC|no2019048471‏
996 ‎‡2 SUDOC|27118440X‏
996 ‎‡2 LC|n 92055833‏
996 ‎‡2 BIBSYS|90507015‏
996 ‎‡2 SUDOC|033510512‏
996 ‎‡2 BIBSYS|90726596‏
996 ‎‡2 CAOONL|ncf10341924‏
996 ‎‡2 BNF|12435575‏
996 ‎‡2 BIBSYS|14052459‏
996 ‎‡2 LC|nr2003022518‏
996 ‎‡2 NUKAT|n 00022984‏
996 ‎‡2 BIBSYS|14046615‏
996 ‎‡2 BIBSYS|1634281493355‏
996 ‎‡2 RERO|A023944280‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏